NRC Health Reports 4% Revenue Growth to $35.4 Million in Q2 2026

NRC Health reported its financial results for the second quarter of 2026, revealing a revenue increase of 4% to $35.4 million compared to $34.0 million in the same period last year. For the first half of 2026, total revenue reached $70.2 million, up from $67.6 million in the prior year. The growth was primarily driven by a $1.2 million increase in recurring revenue from existing customers and $0.9 million from new customers, although this was partially offset by $0.7 million in contra-revenue related to third-party solutions. Despite the revenue growth, the company experienced an operating loss of $3.2 million for the quarter, a significant decline from the $1.6 million operating income reported in Q2 2025.

The company's operating expenses rose sharply, with total operating expenses increasing to $38.6 million in Q2 2026 from $32.5 million in the previous year. This rise was largely attributed to a $7.1 million increase in stock-based compensation expenses related to executive leadership transitions, alongside higher direct expenses associated with survey delivery services and technology investments. Selling, general, and administrative expenses also saw a notable increase, climbing to $22.9 million from $17.7 million year-over-year. The effective tax rate for the quarter was 28%, a decrease from 118% in the prior year, primarily due to the shift from a pre-tax income to a loss.

In terms of operational metrics, NRC Health reported a total recurring contract value (TRCV) of $151.9 million as of June 30, 2026, an 11% increase from $137.0 million a year earlier. The company’s cash flow from operating activities improved significantly, totaling $8.6 million for the first half of 2026, compared to $5.5 million in the same period of 2025. However, cash and cash equivalents decreased to $3.3 million from $4.1 million at the end of the previous fiscal year, primarily due to share repurchases and dividend payments.

NRC Health has also been active in its capital allocation strategy, with a stock repurchase program authorized for up to $60 million through March 2028. In the second quarter, the company repurchased 397,381 shares for approximately $7.4 million. The company continues to focus on its subscription-based service model, which is expected to drive future revenue growth. Looking ahead, NRC Health anticipates that maintaining growth in TRCV will lead to increased revenue in subsequent periods, although it acknowledges potential risks including market competition and economic conditions that could impact its operations.